Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2025-12-26 @ 2:10 AM
Study NCT ID:
NCT00001805
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
1999-03
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2000-06
Completion Date Type:
None
First Submit Date:
1999-11-03
First Submit QC Date:
None
Study First Post Date:
2002-12-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2008-03-03
Last Update Post Date:
2008-03-04
Last Update Post Date Type:
ESTIMATED